Linked Life Data

18633213

Source:http://linkedlifedata.com/resource/pubmed/id/18633213

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-7-17
pubmed:abstractText
Intraperitoneal (i.p.) chemotherapy targets i.p. regional metastasis by maintenance of high-dose intensity. Thus, it is applied for cancers in which i.p. lesions limit the prognosis or QOL of patients. In ovarian cancer, ample evidence to support survival benefit of i.p. chemotherapy has been established, however, its standardization has not yet been accomplished. NCI has made efforts for the dissemination of and education in i.p. therapy, and GOG's research focuses on a less toxic i.p. regimen. In gastric cancer, the advantage of i.p. therapy has not been proved, and for its approval, phase I-III trial of i.p. with or without cytoreduction surgery should be initiated.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
881-4
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
[Evidence and issues in standardization of intraperitoneal chemotherapy].
pubmed:affiliation
Gastrointestinal Surgery, Kanagawa Cancer Center, Asahi-ku, Yokohama, Japan.
pubmed:publicationType
Journal Article, English Abstract